drugset / Trial / NCT05578287
RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
As an established therapeutic target, HER2 is widely used in a variety of tumors, including breast cancer and gastric cancer, among which a variety of drugs, including trastuzumab, lapatinib and T-DM1, have been approved for the treatment of breast cancer and gastric cancer with HER2 amplification or overexpression. In colorectal cancer, HER2 as a target has also been focused in recent years.
Timeline
- Start
- 2023-07-18
- Primary completion
- 2024-12-15
- Completion
- 2025-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 0.5 g | — |
| Subject | Celecoxib | Other / unclassified | 200 mg | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | — |
| Subject | Tislelizumab | Monoclonal antibody | 2 mg/kg | — |